Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NUTEX HEALTH INC. reported revenue of $875M, up 82.4% year over year. Operating margin was 31.5% and net margin 8.1%, on a free-cash-flow margin of 28.1% with capital expenditure at 0.3% of revenue. Every figure is computed directly from NUTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $875M | 31.5% | 8.1% |
| FY2024 | $480M | 27.2% | 10.9% |
| FY2023 | $248M | -12.8% | -18.5% |
| FY2022 | $219M | -185.4% | -193.7% |
| FY2021 | $332M | 51.4% | 40.0% |
How does NUTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: ABM · ACIW · ACN · ACVA · ADBE · ADMQ
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.